CN112569163A - 一种不含防腐剂的抗敏修复乳液及其制备方法 - Google Patents
一种不含防腐剂的抗敏修复乳液及其制备方法 Download PDFInfo
- Publication number
- CN112569163A CN112569163A CN201910929050.0A CN201910929050A CN112569163A CN 112569163 A CN112569163 A CN 112569163A CN 201910929050 A CN201910929050 A CN 201910929050A CN 112569163 A CN112569163 A CN 112569163A
- Authority
- CN
- China
- Prior art keywords
- allergy
- skin
- emulsion
- extract
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 93
- 239000000839 emulsion Substances 0.000 title claims abstract description 92
- 230000008439 repair process Effects 0.000 title claims abstract description 89
- 239000003755 preservative agent Substances 0.000 title claims abstract description 27
- 230000002335 preservative effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 230000004888 barrier function Effects 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
- 239000003381 stabilizer Substances 0.000 claims abstract description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 12
- 239000011734 sodium Substances 0.000 claims abstract description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 10
- 108010020346 Polyglutamic Acid Proteins 0.000 claims abstract description 10
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims abstract description 10
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 10
- 239000002738 chelating agent Substances 0.000 claims abstract description 8
- 239000003974 emollient agent Substances 0.000 claims abstract description 8
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims abstract description 8
- 239000002562 thickening agent Substances 0.000 claims abstract description 8
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 65
- 239000002994 raw material Substances 0.000 claims description 28
- 230000007794 irritation Effects 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 20
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- -1 natural VE Chemical compound 0.000 claims description 12
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 11
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 11
- 229940036350 bisabolol Drugs 0.000 claims description 11
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 claims description 10
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 10
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 10
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 10
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 claims description 10
- 229940048864 ceramide 1 Drugs 0.000 claims description 10
- 229940044176 ceramide 3 Drugs 0.000 claims description 10
- 229940119170 jojoba wax Drugs 0.000 claims description 10
- 229940057910 shea butter Drugs 0.000 claims description 10
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 9
- 241000219357 Cactaceae Species 0.000 claims description 9
- 240000003183 Manihot esculenta Species 0.000 claims description 9
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 9
- 240000005546 Piper methysticum Species 0.000 claims description 9
- 235000016787 Piper methysticum Nutrition 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 229930182478 glucoside Natural products 0.000 claims description 9
- 150000008131 glucosides Chemical class 0.000 claims description 9
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 9
- 229940095110 selaginella tamariscina extract Drugs 0.000 claims description 9
- 229940032094 squalane Drugs 0.000 claims description 9
- 244000144927 Aloe barbadensis Species 0.000 claims description 8
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 8
- 241000045403 Astragalus propinquus Species 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 235000011399 aloe vera Nutrition 0.000 claims description 8
- 235000006533 astragalus Nutrition 0.000 claims description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 7
- 241000246044 Sophora flavescens Species 0.000 claims description 7
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 7
- 241000305491 Gastrodia elata Species 0.000 claims description 6
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims description 6
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229960000735 docosanol Drugs 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 240000007185 Albizia julibrissin Species 0.000 claims description 3
- 235000011468 Albizia julibrissin Nutrition 0.000 claims description 3
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 229940043375 1,5-pentanediol Drugs 0.000 claims 1
- 241001180873 Saposhnikovia divaricata Species 0.000 claims 1
- 229940002386 calendula officinalis extract Drugs 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 229940051250 hexylene glycol Drugs 0.000 claims 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 12
- 210000003491 skin Anatomy 0.000 description 105
- 230000000694 effects Effects 0.000 description 43
- 238000002474 experimental method Methods 0.000 description 41
- 230000000052 comparative effect Effects 0.000 description 26
- 208000024891 symptom Diseases 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 16
- 208000003251 Pruritus Diseases 0.000 description 13
- 229940060184 oil ingredients Drugs 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 230000008591 skin barrier function Effects 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000007803 itching Effects 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 229960001340 histamine Drugs 0.000 description 8
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 7
- 241000132025 Calendula Species 0.000 description 7
- 235000003880 Calendula Nutrition 0.000 description 7
- 108010003272 Hyaluronate lyase Proteins 0.000 description 7
- 102000001974 Hyaluronidases Human genes 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 229960002773 hyaluronidase Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 230000037307 sensitive skin Effects 0.000 description 7
- 229940083542 sodium Drugs 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 210000003837 chick embryo Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 241000220433 Albizia Species 0.000 description 5
- 235000011438 Albizia odoratissima Nutrition 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000007797 corrosion Effects 0.000 description 4
- 238000005260 corrosion Methods 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010040830 Skin discomfort Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 150000002559 kavalactones Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 3
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 241000305492 Gastrodia Species 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001180876 Saposhnikovia Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N beta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000012938 design process Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000004047 hyperresponsiveness Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- GZYFIMLSHBLMKF-REOHCLBHSA-N L-Albizziine Chemical compound OC(=O)[C@@H](N)CNC(N)=O GZYFIMLSHBLMKF-REOHCLBHSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 239000006114 chemosensitizer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 231100000821 endpoints of toxicity testing Toxicity 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9741—Pteridophyta [ferns]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种不含防腐剂的抗敏修复乳液及其制备方法,旨在提供一种能够提高皮肤的耐受度,增强皮肤的屏障功能,抗敏修复受损肌肤的乳液;其技术方案包括下述重量份组分:多元醇5‑15份,增稠剂0.1‑0.4份,螯合剂0.01‑0.1份,透明质酸钠0.1‑0.5份,聚谷氨酸钠0.1‑0.3份,舒缓抗敏因子2‑6份,抑制刺激因子1.1‑2.8份,屏障修复因子1‑4份,乳化稳定剂2‑4份,润肤剂15‑20份,氨甲基丙醇0.2‑0.5份,对羟基苯乙酮0.2‑0.4份,辛酰羟肟酸0.3‑0.7份,余量为水;属于化妆品技术领域。
Description
技术领域
本发明公开了一种乳液,具体地说,是一种具有抗敏修复作用的乳液,本发明还公开了该乳液的制备方法,属于化妆品技术领域。
背景技术
肌肤体质,是肌肤对外界刺激(空气中的小颗粒,如花粉、粉尘等。环境,护肤品、气候变化等)的防御和适应力。一般来讲,好的肌肤体质,才能更好的恰当的防御外界刺激,维持肌肤的健康状态。对于敏感肌肤,当外界刺激侵袭肌肤时,角质化细胞和肥大细胞会释放出各种炎症介质,引起肌肤的灼烧感、刺痛感和紧绷感等,并伴随瘙痒,从而引起肌肤发红,出现红斑,引起肌肤的敏感。而恰当的防御力,会抑制各种炎症介质的释放,减弱肌肤的灼烧、刺痛等不适感。
敏感肌是新近产生的皮肤症状术语,是目前最常见的皮肤不适症状,严重影响着人们的生活质量。该术语通常被自认为具有面部过度反应症状的个体用于形容自己的肌肤,认为自己的肌肤较常人更容易受到外界环境或面部产品的侵害产生过度反应。敏感肌是一种生理学反应症状,而非疾病。
敏感肌人群的皮肤症状大致表现为,感官上出现面部紧绷感,刺痛感,麻痒感,灼烧感,并伴随有疼痛、持续性的痒感等。皮肤的视觉症状为红斑和皮肤潮红症状。
据不完全统计,目前全球敏感肌肤人群接近50%,而自认为自身出现过不同程度的皮肤过敏症状的人群达80%以上。导致肌肤敏感的因素多种多样,大致表现为:环境的变化,化学类致敏源的接触,日常的过度清洁,生活和工作的多度压力,生活不规律。熬夜,饮食不规律等。由于引起肌肤敏感的因素多种多样,敏感症状也因人而异,因此解决肌肤敏感问题,提升肌肤的舒适度,需要紧密结合市场的需求,从源头了解导致肌肤敏感的原因,全面考虑针对敏感肌的解决方案,一方面要防敏,另一方面要做到对已受损,并伴有敏感肌肤症状的肌肤的修复。
近年来针对肌肤敏感的产品还只是停留在概念宣称层面,并不能从源头上真正解决肌肤的敏感症状,使用的抗敏功效原料也只是各种原料的堆积,并没有相应的数据支撑资料。体外和人群测试等方面的数据也无从查起,所以针对肌肤敏感问题,并不能达到相应的效果。相反,部分具有抗敏修复功效的化妆品,由于在原料筛选过程中,并未从敏感肌肤的肌肤体质着手,而过度的追求“即时”“高效”的效果,选择添加大量的化学制剂和激素类物质,这些原料不大会产生肌肤依赖性,还能加重肌肤的的敏感和不适症状,导致肌肤毛孔粗大,丘疹、红斑、肌肤暗沉、粉刺等现象加重,使肌肤受损情况越来越严重,肌肤耐受性也会受到很大程度的损伤;而针对敏感肌肤的药物,通常具有各种的副作用,并伴有一定的药物依赖性,导致敏感肌肤人群的肌肤防御力越来越差,屏障受损越来越严重。
发明内容
针对上述问题,本发明的第一目的是提供一种不含防腐剂的抗敏修复乳液,该抗敏修复乳液不含防腐剂、不添加色素和香精,原料来源天然、安全、无刺激,且添加舒缓抗敏因子组合物,降低肌肤的红肿、发痒、刺痛等不适症状,同时添加屏障修复因子,改善肌肤的屏障受损问题,提高肌肤的耐受性,从而使乳液达到保湿肌肤,舒缓现有敏感症状,修复肌肤屏障,提高肌肤耐受性的作用。
本发明的第二个目的是提供一种抗敏修复乳液的制备方法,该方法操作简单,容易实现,工艺过程控制方便,生产效率较高,耗能少,在现有抗敏修复功效配方中成本较低,可实现大规模的工业生产。
为此,本发明提供的第一个目的是这样的:
一种不含防腐剂的抗敏修复乳液,包括如下重量份的原料:多元醇5-15份,增稠剂0.1-0.4份,螯合剂0.01-0.1份,透明质酸钠0.1-0.5份,聚谷氨酸钠0.1-0.3份,舒缓抗敏因子10-15份,抑制刺激因子1.1-2.8份,屏障修复因子1-4份,乳化稳定剂2-4份,润肤剂15-20份,氨甲基丙醇0.3-0.5份,对羟基苯乙酮0.2-0.4份,辛酰羟肟酸0.3-0.7份,余量为水。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述的多元醇为甘油、丁二醇、戊二醇、己二醇、丙二醇中的至少两种。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述的增稠剂为卡波姆、黄原胶、鲸蜡硬脂醇、山嵛醇中的至少两种。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述的螯合剂为EDTA-2Na。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述的舒缓抗敏因子由膜荚黄芪提取物,库拉索芦荟提取物,苦参提取物,金盏花提取物,防风提取物,天麻提取物,合欢花提取物,黄岑提取物按照质量比1-3:0.5-1:0.6-1:2-3:1.5-2:0.5-1:1-3:0.6-1.2混合而成的。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述的抑制刺激因子由卡瓦提取物、仙人掌提取物、木薯淀粉按照质量比0.1-0.8:0.5-1:0.5-1混合而成的。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述的屏障修复因子由神经酰胺1、神经酰胺3、神经酰胺6、天然VE、红没药醇、植物甾醇、脂肪酸和卷柏提取物按照质量比0.5-1:0.5-1:0.5-1:-0.5:0.5-1:0.5-1:0.5-1:1-1.5混合而成的。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述乳化稳定剂为氢化卵磷脂、山梨坦橄榄油酸酯、鲸蜡硬脂基葡糖苷、聚甘油-3甲基葡糖二硬脂酸酯中的至少三种。
进一步的,上述的不含防腐剂的抗敏修复乳液,所述润肤剂为牛油果树果脂油、角鲨烷、霍霍巴油、异壬酸异壬酯、棕榈酸乙基己酯、辛酸癸酸甘油三酯的组合物。
本发明提供的第二个技术方案是这样的:
该不含防腐剂的抗敏修复乳液的制备方法,依次包括下述步骤:
1)称取各种组分;
2)将步骤1)称取的多元醇、螯合剂、透明质酸钠、增稠剂、聚谷氨酸钠、对羟基苯乙酮加入余量水中,搅拌溶解加热至75-85℃,并继续搅拌10-15min至完全溶解,得水相;
3)将步骤1)称取的乳化稳定剂加入润肤剂中,搅拌溶解加热至75-80℃,并继续搅拌5-8min至完全溶解得油相;
4)将步骤3)油相加入步骤2)水相,搅拌均匀后,均质3-5min,至形成均一稳定的乳状液,并保温搅拌10-15min,降温;
5)降温至45-50℃,依次加入氨甲基丙醇、辛酰羟肟酸、舒缓抗敏因子、抑制刺激因子、屏障修复因子,然后搅拌均匀,降温至40℃以下出料得抗敏修复乳液。
与现有技术相比,本发明提供的技术方案具有如下技术优点:
1、本发明提供的技术方案中所用的舒缓抗敏因子,原料本身性质温和,安全性极高,不会给人体带来不适感,同时还能有效提高抗敏修复乳液的舒缓、抗敏功效,缓解外界光照、环境污染等对肌肤引起的不良刺激反应:其中,膜荚黄芪提取物,对机体免疫系统具有广泛的调节作用,能够增强巨噬细胞的活性,促进细胞因子的产生,促进T淋巴细胞的增强,从而达到全面提高肌肤的免疫防御功能,增加肌肤肌体抵抗外界不良刺激的作用;库拉索芦荟能够消除肌肤炎症,保湿肌肤,抵抗肌肤的敏感症状,达到很好的修复受损肌肤的作用;苦参可用作抗菌抑菌剂、抗炎剂,能够有效缓解肌肤现有炎症,减少肌肤炎症反应;金盏花提取物能够消除肌肤炎症,抑菌抗菌;防风、天麻能够抑制二硝基氯苯引起的迟发性超过敏反应,能够达到抗炎、抗过敏的效果。合欢花中含有的合欢甙、鞣质,能够起到很好的镇静安神作用;还能收缩肌肤的毛孔,改善毛孔粗大问题;黄岑提取物中含有黄岑苷和黄岑苏,具有广泛的抗菌作用,能够抑制金黄色葡萄球菌、溶血性链球菌等有害菌,具有很好的抑制痤疮引起的肌肤问题,同时还具有一定的防腐功效,能够减少化妆品中防腐剂的添加量;黄岑苷能够显著拮抗因组胺引起的瘙痒过敏症状,阻止过敏反应介质的释放,还能抑制透明质酸酶的活性,具有高效的抗过敏作用;总而言之,本发明提供的舒缓抗敏因子“整体、辨证、综合”的思想,针对分析过敏产生的机理,按照“君、臣、佐、使”的组方原则,将膜荚黄芪、防风、天麻、金盏花、合欢花等草本悉心配伍,形成具备抗敏功效的化妆品植物功效原料。实验分别采用磷酸致痒域法、被动皮肤反应法、豚鼠皮肤脱水模型、人体评价等研究舒敏佳分别对安抚止痒、祛红消肿、敏后修复和舒缓肌肤的功效进行验证。可综合预防和降低化妆品配方中的常见刺激原引起的刺激和敏感现象。同时还能在一定程度上修复保护细胞膜、抑制DNA损伤
2、本发明提供技术方案中所述抑制刺激因子中含有卡瓦提取物和仙人掌提取物和木薯淀粉,卡瓦提取物中,含有多种卡瓦内酯,相较于单一的卡瓦内酯,复合的卡瓦内酯相互间具有协同增效的效果,具有更高的活性,并且具有杀菌,消除肌肤的有害菌;复配仙人掌提取物和木薯粉提取物通过修复因刺激引起的细胞膜损伤和DNA损伤,可以综合预防和降低化妆品配方中常见的刺激原引起的刺激和敏感现象。
3、本发明提供技术方案中屏障修复因子中含有神经酰胺1,神经酰胺3,神经酰胺6,红没药醇、天然VE、植物甾醇、脂肪酸,卷柏提取物;其中,神经酰胺1,神经酰胺3,神经酰胺6,脂肪酸,植物甾醇构成了肌肤的主要“砖墙结构”,形成了类脂屏障,能够有效对抗因干燥、敏感和老化引起的过度的水分散失;卷柏提取物,作用细胞激活剂,能够显著的激活丝聚蛋白的活性,促进水分停留在角质层,有效减少肌肤的光老化作用,诱导两种生长因子的合成,从而引起真皮细胞的增殖,还能增加细胞的活力,达到改善肌肤屏障的作用;天然生育酚包含天然存在的α、β、γ、δ生育酚混合体,能够在一定程度上保护成品不被氧化,延长产品的保质期,同时还能在一定程度上修复皮肤,增加皮肤的光泽和滋润感,在与红没药醇结合,能够保护和护理过敏肌肤,研究还表明红没药醇具有很好的抑菌作用;能够通过减少炎症因子的释放,改善肌肤的红肿、红斑、瘙痒等不适症状。达到对炎症的预防和抑制作用。
4、本发明提供的方案中没有添加防腐剂,避免了防腐剂对肌肤的刺激性,提高了配方整体的安全温和性,配方中不添加防腐剂,切断了防腐剂对肌肤的刺激性。另外,配方中添加了舒缓抗敏因子和屏障修复因子组合物。第一,引入植物提取功效原料抑制刺激因子,减轻化妆品原料/外界刺激等可能给肌肤带来不适感。第二,引入功效原料,舒缓抗敏因子,舒缓过敏症状。第三,引入的功效原料,屏障修复因子能够提高皮肤的耐受度,一方面降低皮肤的过度反应;另一方面增强皮肤的屏障功能,修复受损肌肤;具有极好的温和安全性,适合任何肌肤体质的人群使用。
5、本发明提供的技术方案中制备抗敏修复乳液,原料来源安全无害。配方中没有添加常规的防腐剂(苯氧乙醇、尼泊金甲酯等),而是通过添加对羟基苯乙酮和辛酰羟肟酸,达到防腐,延长货架期稳定性的目的。对羟基苯乙酮和辛酰羟肟酸的添加比例,通过防腐挑战,证明具有较好的防止微生物滋生的效果。配方在设计过程中,严格控制各原料的添加量,使所用原料之间的配合度达到很好的效果,协同增效。配方大量植物来源油脂,霍霍巴油、角鲨烷和牛油果树果脂油和透明质酸钠作为配方的主体原料,起到舒缓肌肤、提高肌肤滋润度,补水保湿等效果。在舒缓肌肤的基础上进行肌肤屏障作用的修复,补充肌肤所需的脂质结构,提升肌肤抵抗外界刺激的耐受度。
6、本发明提供的方案中该抗敏修复乳液的制备工艺,该工艺操作简单,容易控制,在实际生产中,具有很高的生产效率,可实现大规模的生产制作。
附图说明
图1是实施例2与对比试验比抑制透明质酸酶结果;
图2是实施例2和对比实验6对经SDS处理的血红细胞溶血率的影响。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部实施例。对于未特别注明的工艺参数或者条件,可参照常规技术进行。
实施例1
本发明提供的一种不含防腐剂的抗敏修复乳液,每100g包括如下重量数的原料:甘油3g,丁二醇4g,卡波姆0.2g,黄原胶0.2g,EDTA-2Na0.01g,透明质酸钠0.5g,聚谷氨酸钠0.1g,舒缓抗敏因子3g,卡瓦提取物0.8g,仙人掌提取物1g,木薯淀粉1g,屏障修复因子4g,氢化卵磷脂1g,山梨坦橄榄油酸酯1g,鲸蜡硬脂基葡糖苷1g,牛油果树果脂油2g,角鲨烷2g,霍霍巴油2g,异壬酸异壬酯2g,棕榈酸乙基己酯4g,辛酸癸酸甘油三酯3g,氨甲基丙醇0.3g,对羟基苯乙酮0.4g,辛酰羟肟酸0.3-0.7g,余量为水。
上述的舒缓抗敏因子由膜荚黄芪提取物,库拉索芦荟提取物,苦参提取物,金盏花提取物,防风提取物,天麻提取物,合欢花提取物,黄岑提取物按照质量比3:0.5:1:2:2:0.5:3:0.6混合而成的。
上述的屏障修复因子由神经酰胺1、神经酰胺3、神经酰胺6、天然VE、红没药醇、植物甾醇、脂肪酸和卷柏提取物按照质量比1:0.5:0.5:0.5:0.5:0.8:0.7:1.3混合而成的。
实施例2
本发明提供的一种不含防腐剂的抗敏修复乳液,每100g包括如下重量数的原料:戊二醇2g,己二醇2g,丙二醇1g,黄原胶0.2g,鲸蜡硬脂醇0.1g,EDTA-2Na0.01-0.1g,透明质酸钠0.1-0.5g,聚谷氨酸钠0.1-0.3g,舒缓抗敏因子1-3g,卡瓦提取物0.1g,仙人掌提取物1g,木薯淀粉0.5g,屏障修复因子1-4g,乳化稳定剂氢化卵磷脂0.5g,山梨坦橄榄油酸酯0.5g,鲸蜡硬脂基葡糖苷1g,氢化卵磷脂1g,山梨坦橄榄油酸酯1g,鲸蜡硬脂基葡糖苷1g,牛油果树果脂油2g,角鲨烷2g,霍霍巴油3g,异壬酸异壬酯3g,棕榈酸乙基己酯4g,辛酸癸酸甘油三酯4g,氨甲基丙醇0.5g,对羟基苯乙酮0.2-0.4,辛酰羟肟酸0.3-0.7g,余量为水。
上述的舒缓抗敏因子由膜荚黄芪提取物,库拉索芦荟提取物,苦参提取物,金盏花提取物,防风提取物,天麻提取物,合欢花提取物,黄岑提取物按照质量比2:0.8:0.6:2.5:1.5:1:1.2:1.2混合而成的。
上述的屏障修复因子由神经酰胺1、神经酰胺3、神经酰胺6、天然VE、红没药醇、植物甾醇、脂肪酸和卷柏提取物按照质量比0.5:0.8:0.8:0.2:0.7:1:1:1混合而成的。
实施例3
本发明提供的一种不含防腐剂的抗敏修复乳液每100g包括如下重量数的原料:甘油10g,己二醇5g,鲸蜡硬脂醇0.05g,山嵛醇0.05g,EDTA-2Na0.01-0.1g,透明质酸钠0.1-0.5g,聚谷氨酸钠0.1-0.3g,舒缓抗敏因子3g,卡瓦提取物0.5g,仙人掌提取物0.8g,木薯淀粉0.7g,屏障修复因子1-4g,氢化卵磷脂1g,山梨坦橄榄油酸酯1g,鲸蜡硬脂基葡糖苷1g,牛油果树果脂油1g,角鲨烷3g,霍霍巴油5g,异壬酸异壬酯2g,棕榈酸乙基己酯3g,辛酸癸酸甘油三酯4g,氨甲基丙醇0.4g,对羟基苯乙酮0.2-0.4,辛酰羟肟酸0.3-0.7g,余量为水。
上述的舒缓抗敏因子由膜荚黄芪提取物,库拉索芦荟提取物,苦参提取物,金盏花提取物,防风提取物,天麻提取物,合欢花提取物,黄岑提取物按照质量比1:0.7:0.7:3:1.8:0.6:1:1.0混合而成的。
上述的屏障修复因子由神经酰胺1、神经酰胺3、神经酰胺6、天然VE、红没药醇、植物甾醇、脂肪酸和卷柏提取物按照质量比0.8:1:0.8:0.3:1:0.5:0.8:1.2混合而成的。
实施例4
本发明提供的一种不含防腐剂的抗敏修复乳液,每100g包括如下重量数的原料:甘油2g,丁二醇2g,戊二醇3g,己二醇3g,卡波姆0.1g,鲸蜡硬脂醇0.1g,山嵛醇0.1g,EDTA-2Na0.01-0.1g,透明质酸钠0.1-0.5g,聚谷氨酸钠0.1-0.3g,舒缓抗敏因子1-3g,卡瓦提取物0.3g,仙人掌提取物0.7g,木薯淀粉0.5g,屏障修复因子1-4g,氢化卵磷脂1g,山梨坦橄榄油酸酯0.5g,鲸蜡硬脂基葡糖苷1g,牛油果树果脂油3g,角鲨烷3g,霍霍巴油4g,异壬酸异壬酯3g,棕榈酸乙基己酯4g,辛酸癸酸甘油三酯3g,氨甲基丙醇0.3g,对羟基苯乙酮0.2g,辛酰羟肟酸0.3-0.7g,余量为水。
上述的舒缓抗敏因子由膜荚黄芪提取物,库拉索芦荟提取物,苦参提取物,金盏花提取物,防风提取物,天麻提取物,合欢花提取物,黄岑提取物按照质量比1.5:1:0.8:2.8:1.6:0.8:2:0.8混合而成的。
上述的屏障修复因子由神经酰胺1、神经酰胺3、神经酰胺6、天然VE、红没药醇、植物甾醇、脂肪酸和卷柏提取物按照质量比0.7:0.7:0.8:0.4:0.8:0.6:0.6:1.5混合而成的。
为了更好的说明本申请的优点,下面给出本申请提供的技术方案的对比实验例
对比实验1,相比于实施例2,去掉羟基苯乙酮和辛酰羟肟酸;
其中对比实验2-4,是为了证明实施例具有极好的肤感体验,
对比实验2,相比于实施例2,将牛油果树果脂油用凡士林等量替换;
对比实验3,相比于实施例2,将氢化卵磷脂用等量的吐温20替换;
对比实验4,相比于实施例2,将霍霍巴油用等量的氢化聚异丁烯替换;
对比实验5相比实施例2,去掉舒缓抗敏因子;
对比实验6相比实施例2,去掉抑制刺激因子;
对比试验7相比实施例2,去掉屏障修复因子;
实施中的乳液制备工艺:
1)称取各种组分;
2)将步骤1)称取的多元醇、螯合剂、透明质酸钠、增稠剂、聚谷氨酸钠、对羟基苯乙酮加入余量水中,搅拌溶解加热至75-85℃,并继续搅拌10-15min至完全溶解,得水相;
3)将步骤1)称取的乳化稳定剂加入润肤剂中,搅拌溶解加热至75-80℃,并继续搅拌5-8min至完全溶解的油相;
4)将步骤3)油相加入步骤2)水相,搅拌均匀后,均质3-5min,至形成均一稳定的乳状液,并保温搅拌10-15min,降温;
5)降温至45-50℃,依次加入氨甲基丙醇、辛酰羟肟酸、舒缓抗敏因子、抑制刺激因子、屏障修复因子,然后搅拌均匀,降温至40℃以下出料得抗敏修复乳液。
为了证明本发明不含防腐剂的抗敏修复乳液的证明实验
1.防腐挑战测试结果:
配方中未添加防腐剂,而是采用保湿剂对其货架期的稳定进行保证,从而减少防腐剂引入给肌肤带来的过敏等不适感,又确保配方不致在保质期内受微生物的过度侵害。该保湿剂的添加量是通过防腐挑战测试,并证明在相应的货架期内,细菌和霉菌的含量在化妆品卫生安全许可范围内。具体测试结果如表1和表2:
表1防腐挑战测试数据结果(细菌)
表2防腐挑战测试数据结果(霉菌)
防腐挑战结果表明,实施例2中添加对羟基苯乙酮和辛酰羟肟酸,能够在一定程度上抑制抗敏修复乳液中细菌和霉菌的产生,防止产品中微生物过量,确保了产品在长期货架期的稳定性。而对比实验1中未加羟基苯乙酮和辛酰羟肟酸,显示出细菌和霉菌的超标,没有通过相关的防腐挑战实验;
2人群试用--肤感体验
本发明申请针对产品的肤感体验感进行了人群试用,并收集了相关的试用反馈结果。实验进行了实施例1,2,3的实验,并进行了对比实验2,3,4。对比实验2,3,4在保证产品稳定性通过的前提下,对用到的油脂和乳化剂等进行了相应的调整。实验主要从配方整体的涂抹性,吸收性,滋润度,油腻感等方面进行指标的筛选。
表3抗敏修复乳液实施例1,2,3和对比实验2-4的感官评价结果
本申请实施例中采用的油脂主要为角鲨烷,霍霍巴油,牛油果树果脂油,异壬酸异壬酯,乳化稳定剂为氢化卵磷脂、山梨坦橄榄油酸酯和鲸蜡硬脂基葡糖苷的混合物,乳化剂和油脂按一定比例搭配,能够保证配方的稳定性,同时还能提供滋润,柔软、易吸收、已推抹的肤感体验;对比实验2-4中,相比于实施例2,更换配方中的油脂或乳化稳定剂,均表现出吸收缓慢,推抹性不佳等不愉悦的体验感。说明实施例具有很好的配伍性,能够带来很好的肤感体验。
并且在抗敏修复乳液中添加乳化稳定剂,达到配方长期稳定性的作用,同时,山梨坦橄榄油酸酯和鲸蜡硬脂基葡糖苷,作为组合乳化剂,为植物来源,性质温和,安全性高。同时具有很好的乳化效果。另外制得的抗敏修复乳液稳定性极佳,能使乳液中用到的油分很好的分散在水相中,并能保持长期稳定性,肤感上,有较好的质地和极佳的涂抹性,吸收较快。氢化卵磷脂,取自大豆,具有抗炎症作用的天然乳化剂,能有效减少刺激,降低其他表面活性剂的潜在刺激性。实验结果还发现,采用氢化卵磷脂作为乳化剂制得抗敏修复乳液贴肤性极好,并且不会带来黏腻不适感;
3、功效验证试验
配方中添加舒缓抗敏因子、抑制刺激因子和屏障修复因子,分别从改善肌肤敏感、降低配方/环境刺激和修复受损肌肤屏障等维度,改善肌肤不适症状;以下实验分别从抑制组胺释放、降低肌肤刺激性和减少肌肤经皮水分散失值(TWEL)等衡量本发明的优越性;
(1)舒缓抗敏功效实验验证
将膜荚黄芪、库拉索芦荟、苦参、金盏花提取物、防风、天麻、黄岑提取物、合欢配伍,形成具备抗敏功效的化妆品舒缓抗敏因子。实验通过测定实施例和对比实验对抑制组胺释放的能力进行判定其舒缓抗敏功效;
抑制组胺释放的能力可以通过抑制透明质酸酶进行判定。对透明质酸酶的抑制率越高,其抑制组胺释放的能力越强。也即舒缓抗敏功效越强。实验证明实施例和对比实验相比,具有较强的抑制透明质酸酶活性的能力,其效果图1所示,根据图1可知,实施例2中,透明质酸酶抑制率达到70.7%,对比实验5相较于实施例2,其他组分不变,去掉舒缓抗敏因子组合物,其抑制透明质酸酶率仅为6.56%。即实施例具有很好的抑制组胺释放的能力,而对比实验不含舒缓抗敏因子,其抑制组胺释放的能力极弱。实验结果表明,舒缓抗敏因子能够显著抑制因组胺释放而引起的瘙痒等敏感症状;
(2)抑制刺激功效实验验证
所述的抑制刺激因子包括卡瓦提取物,仙人掌提取物和木薯淀粉。抑制刺激因子能够有效抑制因常见致敏源(防腐剂、香精和表面活性剂等)引起的刺激反应。综合预防和降低化妆品配方中常见刺激原引起的刺激和敏感现象。
为了证明抑制刺激因子对常见刺激原的抑制作用,实验采用十二烷基硫酸钠(SDS)作为表面活性剂的刺激原,刺激血红细胞溶血,血红细胞的溶血率随表面活性剂的添加量增加而上升,在0.4%的SDS添加量时,会出现明显的红细胞溶血现象;
实验分别进行实验案例2和对比实验6处理上述溶血红细胞,实验结果如图2所示,由图2可知,对于经SDS处理后的血红细胞,其溶血率达100%,为了证明抑制刺激因子对表面活性剂引起的刺激的抑制作用,实验采用实验案例2和对比实验对其进行处理。由实验数据可知,实施例中添加的抑制刺激因子其红细胞溶血率仅为5.3%,其抑制率达94.7%;而对比实验6为不添加抑制刺激因子的实施例2的对比实验,其对于红细胞溶血率为83.7%,抑制率仅为16.3%。从实验结果可知,本发明中添加的抑制刺激因子能够显著抑制因表面活性剂引起的刺激。
(3)屏障修复功效实验验证
本发明通过添加神经酰胺1,神经酰胺3,神经酰胺6,天然VE,红没药醇,植物甾醇,脂肪酸,卷柏提取物等的组合物来达到修复肌肤屏障的效果。资料显示外用脂质浓缩物(神经酰胺1,神经酰胺3,神经酰胺6,植物甾醇,游离脂肪酸)可以增加干燥、敏感和老化肌肤的天然脂质屏障,从源头上减缓肌肤的不适症状。对抗水分散失和外部的不利因素对肌肤的伤害。该脂质浓缩物模拟类脂屏障的天然构成,能够有效重塑脂质屏障。
1、为了验证屏障修复因子对于肌肤屏障修复功能的效果,实验对经SDS处理后第五天的皮肤屏障的完整性的修复结果进行判断(基于经皮水分散失值TWEL)。未经处理和损伤的肌肤,具有很好的肌肤屏障功能,记此时的肌肤含水量为100,损伤后肌肤的水分含量为40,即经过SDS处理后,肌肤的屏障损伤严重,肌肤经皮水分散失严重;
实施例2为添加了屏障修复因子组合物的配方,对比实验7为未添加屏障修复因子组合物的配方,分别用实施例2和对比实验7处理经SDS处理后的肌肤,观察其经皮水分散失值(TWEL),实验结果如表3所示:
表4皮肤屏障修复结果如下表所示
| 实施例 | 肌肤处理方法 | 肌肤水分含量 |
| / | 未处理,未损伤 | 100 |
| / | 未处理 | 40 |
| 实施例2 | 添加屏障修复因子 | 83 |
| 对比实验7 | 未添加屏障修复因子 | 45 |
由上表可知,经SDS处理后的肌肤,表现出明显的经皮水分散失值(TWEL)。通过添加实施例2,即添加含有屏障修复因子组合物的本发明专利的乳液,肌肤的经皮水分散失值(TWEL)得到明显改善,肌肤的含水量提高到83%。而对比实验7中,相比于实施例2,去掉了屏障修复因子组合物,其肌肤水分含量基本没有改善,即对比实验7没有修复肌肤屏障的功能。也即屏障修复因子组合物具有很好的减少肌肤经皮水分散失值。屏障修复因子能够很好的修复受损肌肤的屏障。
4安全性试验
(1)测试方法简述:
绒毛膜尿囊膜血管试验(Chorioallantoicmembranevascularassay,CAMVA)方法通过观察受试物对血管的作用评价潜在的眼刺激性,取14天龄鸡胚,受试物直接接触CAM的小片区域,暴露30分钟后观察CAM血管变化,例如出血或充血(毛细血管扩张)、血管消失(鬼影血管),使50%的受精卵出现这些损伤的受试物浓度被认为是毒性终点。CAMVA试验需要测定10个供试鸡胚出现50%阳性反应所达到的剂量。
(2)结果判定标准:
表5CAMVA试验评分标准
| 血管效应 | 评分 | 观察描述 |
| 无反应 | 0 | 观察不到反应,CAM正常 |
| 鬼影血管 | 1 | 血管内无血流,血管清晰 |
| 毛细血管损伤 | 2 | 充血,或CAM小血管血液增加 |
| 极轻微出血 | 3 | 细小出血点覆盖环内区域不足25% |
| 轻度出血 | 4 | 环内出血点覆盖面积25~50% |
| 中度出血 | 5 | 环内大量出血点或者小区域出血范围到50~75% |
| 严重出血 | 6 | 环内出血点区域﹥75% |
表6护肤化妆品刺激性(CAMVA试验)结果判定标准
表7实施例2CAMVA试验测试结果
注:1)阳性率=阳性反应鸡胚个数/总鸡胚个数×100%,阳性反应指表中评分为1-6分的刺激反应;
2)平均积分=10个测试鸡胚评分之和/10;
从上表可知,本发明抗敏修复乳液实施例2的CAMVA试验阳性率为20%,平均积分为0.6;即本申请涉及的配方具有很好的安全性和温和性;
5人群试用结果--抗敏舒缓功效验证
分别取待测乳液1滴(1泵),涂抹于受试者(18-45岁,样本数60人)的面部和手臂,测试乳液本身对肌肤的刺激性,30min后,面部和手臂均未出现明显的发红、瘙痒等不适症状。从而验证了抗敏修复乳液本身不会引入刺激,不会增加肌肤的不适感。
对受试者进行长期测试,为期1个月,测试人群为面部不同程度的发红、瘙痒、刺痛等症状人群。待测试乳液受试者每天早晚各涂抹一次,受试者每天采用乳液作为唯一的护肤产品,避免其他外界因素的干扰。1个月后,81.67%的受试者均表现了红肿、瘙痒、刺痛症状的缓解和消失。肌肤的光滑细腻感明显改善。测试结果表明,该发明申请中用到的抗敏修复乳液,能够在人群试用中表现出较好的舒敏修复效果。
以上结果显示,抗敏修复乳液的CAMVA试验的平均积分为0.6,平均积分<1.64,因此抗敏修复乳液本身具有安全温和性,不会对人体引起潜在的刺激性或过敏反应。人群试用结果反映了抗敏修复乳液,再次验证了该乳液,不会引入肌肤刺激致敏源,另一方面,该乳液还能在一定程度上缓解现有问题肌肤的红肿、瘙痒、刺痛症状,能够有效的改善问题肌肤的症状,起到舒缓修复的功效。申请中神经酰胺和红没药醇的复配使用,具有很好的协同增效的效果,对肌肤的改善体现在,能够改善肌肤受损的屏障,达到很好的修复作用,减少皮肤经皮水分散失值。
该抗敏修复乳液制备方法简单,制备过程中的工艺容易控制,容易达到预期的效果。另外,整个制备工艺耗时较短,生产效率较高,在现有的具有抗敏功效的乳液中,生产制作成本较低,可实现大规模的生产。另外,通过工艺操作方法,控制所用原料的添加顺序和混合搅拌时间搅拌温度,能够制度具有极佳舒敏、抗刺激、修复、保湿功效的抗敏修复乳液。配方中的霍霍巴油、角鲨烷、牛油果树果脂油、透明质酸钠等,能够提高抗敏修复乳液的保湿滋润感,能够柔软肌肤,提高肌肤的渗透性,增加功效原料在肌肤中的作用表达;
本发明制得的乳液所用到的原料均为安全无害物质,并通过鸡胚绒毛尿囊膜实验,均表现出极好的安全无刺激性,配方中未添加任何防腐剂,对消费者肌肤安全无害,配方在设计过程中,通过严格控制各原料的使用量,确保原料间能够达到很好的配合作用,协同增效,达到最大的抗敏修复功效。本申请采用植物油脂,作为抗敏修复的主要原料,同时在舒缓、抗刺激的基础上,添加舒缓抗敏因子和屏障修复因子,来实现对肌肤的修复和保湿锁水作用,从而使得制得的乳液具有较好的保湿锁水、舒缓抗刺激、修复肌肤屏障的作用,同时确保配方的温和性。
本发明申请所制得的乳液整个过程操作简单,工艺过程容易控制,具有很好的生产效率,制得的抗敏修复乳液,具有很高的抗敏功效,同时成本相对较低,可实现大规模的工业生产。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种不含防腐剂的抗敏修复乳液,包括如下重量份的原料:多元醇5-15份,增稠剂0.1-0.4份,螯合剂0.01-0.1份,透明质酸钠0.1-0.5份,聚谷氨酸钠0.1-0.3份,舒缓抗敏因子2-6份,抑制刺激因子1.1-2.8份,屏障修复因子1-4份,乳化稳定剂2-4份,润肤剂15-20份,氨甲基丙醇0.2-0.5份,对羟基苯乙酮0.2-0.4份,辛酰羟肟酸0.3-0.7份,余量为水。
2.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述的多元醇为甘油、丁二醇、戊二醇、己二醇、丙二醇中的至少两种。
3.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述的增稠剂为卡波姆、黄原胶、鲸蜡硬脂醇、山嵛醇中的至少两种。
4.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述的螯合剂为EDTA-2Na。
5.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述的舒缓抗敏因子由膜荚黄芪提取物,库拉索芦荟提取物,苦参提取物,金盏花提取物,防风提取物,天麻提取物,合欢花提取物,黄岑提取物按照质量比1-3:0.5-1:0.6-1:2-3:1.5-2:0.5-1:1-3:0.6-1.2混合而成的。
6.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述的抑制刺激因子由卡瓦提取物、仙人掌提取物、木薯淀粉按照质量比0.1-0.8:0.5-1:0.5-1混合而成的。
7.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述的屏障修复因子由神经酰胺1、神经酰胺3、神经酰胺6、天然VE、红没药醇、植物甾醇、脂肪酸和卷柏提取物按照质量比0.5-1:0.5-1:0.5-1:-0.5:0.5-1:0.5-1:0.5-1:1-1.5混合而成的。
8.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述乳化稳定剂为氢化卵磷脂、山梨坦橄榄油酸酯、鲸蜡硬脂基葡糖苷的组合物。
9.根据权利要求书1所述的不含防腐剂的抗敏修复乳液,其特征在于,所述润肤剂为牛油果树果脂油、角鲨烷、霍霍巴油、异壬酸异壬酯、棕榈酸乙基己酯、辛酸癸酸甘油三酯的组合物。
10.权利要求1所述的不含防腐剂的抗敏修复乳液的制备方法,其特征在于,依次包括下述步骤:
1)按照权利要求1所述的重量份称取各种组分;
2)将步骤1)称取的多元醇、螯合剂、透明质酸钠、增稠剂、聚谷氨酸钠、对羟基苯乙酮加入余量水中,搅拌溶解加热至75-85℃,并继续搅拌10-15min至完全溶解,得水相;
3)将步骤1)称取的乳化稳定剂加入润肤剂中,搅拌溶解加热至75-80℃,并继续搅拌5-8min至完全溶解得油相;
4)将步骤3)油相加入步骤2)水相,搅拌均匀后,均质3-5min,至形成均一稳定的乳状液,并保温搅拌10-15min,降温;
5)降温至45-50℃,依次加入氨甲基丙醇、辛酰羟肟酸、舒缓抗敏因子、抑制刺激因子、屏障修复因子,然后搅拌均匀,降温至40℃以下出料得抗敏修复乳液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910929050.0A CN112569163B (zh) | 2019-09-28 | 2019-09-28 | 一种不含防腐剂的抗敏修复乳液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910929050.0A CN112569163B (zh) | 2019-09-28 | 2019-09-28 | 一种不含防腐剂的抗敏修复乳液及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112569163A true CN112569163A (zh) | 2021-03-30 |
| CN112569163B CN112569163B (zh) | 2023-01-13 |
Family
ID=75110305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910929050.0A Active CN112569163B (zh) | 2019-09-28 | 2019-09-28 | 一种不含防腐剂的抗敏修复乳液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112569163B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113384514A (zh) * | 2021-06-03 | 2021-09-14 | 绽妍生物科技有限公司 | 一种含有乳酸菌发酵提取物的儿童润肤剂及其制备方法 |
| CN115554197A (zh) * | 2021-12-24 | 2023-01-03 | 宁波久瑞生物工程有限公司 | 一种舒缓修复组合物及其在化妆品中的应用 |
| CN116421513A (zh) * | 2023-03-23 | 2023-07-14 | 上海幸研生物科技有限公司 | 一种敏感肌舒红修护功效的护肤品组合物及其制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130164233A1 (en) * | 2011-12-23 | 2013-06-27 | Ming-Chen Lee | Skin-whitening essence composition containing tyrosinase inhibitor |
| CN107898699A (zh) * | 2017-12-15 | 2018-04-13 | 广东盛美化妆品有限公司 | 一种含铁皮石斛提取物的肌底精华液及其制备方法 |
| CN108096071A (zh) * | 2017-12-15 | 2018-06-01 | 广东巴松那生物科技有限公司 | 一种可修复受损肌肤的精华油及其制备方法 |
| CN108524386A (zh) * | 2018-03-30 | 2018-09-14 | 广东巴松那生物科技有限公司 | 一种不含化学防腐剂的舒缓抗敏护肤乳及其制备方法 |
| CN110200845A (zh) * | 2019-07-05 | 2019-09-06 | 中山中研化妆品有限公司 | 一种用于舒缓修复敏感皮肤的护肤品 |
| CN112569148A (zh) * | 2019-09-28 | 2021-03-30 | 广州市中通生化制品有限公司 | 一种具有舒敏防敏功效的中药组合物及其制备方法与应用 |
-
2019
- 2019-09-28 CN CN201910929050.0A patent/CN112569163B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130164233A1 (en) * | 2011-12-23 | 2013-06-27 | Ming-Chen Lee | Skin-whitening essence composition containing tyrosinase inhibitor |
| CN107898699A (zh) * | 2017-12-15 | 2018-04-13 | 广东盛美化妆品有限公司 | 一种含铁皮石斛提取物的肌底精华液及其制备方法 |
| CN108096071A (zh) * | 2017-12-15 | 2018-06-01 | 广东巴松那生物科技有限公司 | 一种可修复受损肌肤的精华油及其制备方法 |
| CN108524386A (zh) * | 2018-03-30 | 2018-09-14 | 广东巴松那生物科技有限公司 | 一种不含化学防腐剂的舒缓抗敏护肤乳及其制备方法 |
| CN110200845A (zh) * | 2019-07-05 | 2019-09-06 | 中山中研化妆品有限公司 | 一种用于舒缓修复敏感皮肤的护肤品 |
| CN112569148A (zh) * | 2019-09-28 | 2021-03-30 | 广州市中通生化制品有限公司 | 一种具有舒敏防敏功效的中药组合物及其制备方法与应用 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113384514A (zh) * | 2021-06-03 | 2021-09-14 | 绽妍生物科技有限公司 | 一种含有乳酸菌发酵提取物的儿童润肤剂及其制备方法 |
| CN115554197A (zh) * | 2021-12-24 | 2023-01-03 | 宁波久瑞生物工程有限公司 | 一种舒缓修复组合物及其在化妆品中的应用 |
| CN116421513A (zh) * | 2023-03-23 | 2023-07-14 | 上海幸研生物科技有限公司 | 一种敏感肌舒红修护功效的护肤品组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112569163B (zh) | 2023-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111249209B (zh) | 一种保湿修护霜及其制备方法 | |
| US5266318A (en) | Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed | |
| CN113197836A (zh) | 一种保湿舒缓止痒护肤乳霜及其制备方法 | |
| WO2008139182A2 (en) | Skin care composition | |
| WO2024045952A1 (zh) | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 | |
| CN113730272B (zh) | 一种具有缓解眼部疲劳功效的护眼贴及其制备方法 | |
| CN109010115A (zh) | 一种具有抗炎功效的舒敏乳霜 | |
| CN112569163B (zh) | 一种不含防腐剂的抗敏修复乳液及其制备方法 | |
| CN113712873A (zh) | 一种具有祛痘抗炎功效的精华乳组合物及其制备方法 | |
| CN109431943A (zh) | 一种针对婴幼儿湿疹的修护膏及其制备 | |
| CN110638727B (zh) | 一种婴幼儿护臀组合物及其制备方法和应用 | |
| CN113842340B (zh) | 一种抑菌止痒褪红祛痘修复组合物及其应用 | |
| US20060083708A1 (en) | Composition using mineral salts for cosmetic or therapeutic treatment | |
| CN116763705B (zh) | 一种舒缓/抗敏感的组合物、其制备方法和应用 | |
| CN114042027A (zh) | 一种具有敏感肌修护功效的组合物及其制备方法和应用 | |
| CN110897989B (zh) | 一种敏感肌肤修复乳液 | |
| CN114146014B (zh) | 一种复方烟酸薄荷酯植物多糖乳膏及其制备方法 | |
| CN108272672B (zh) | 一种缓解环氧乙醇和多元醇刺激的中药组合物 | |
| EP1261310A1 (de) | Kosmetische und pharmazeutische zubereitungen zur behandlung der cellulite | |
| CN119157808B (zh) | 一种祛红血丝、改善皮肤屏障的组合物及其应用 | |
| CN115844784B (zh) | 一种用于干燥皮肤舒敏抗炎的组合物及其应用和制备方法 | |
| CN116459169B (zh) | 一种抗炎保湿皮肤外用组合物及其制备方法和应用 | |
| CN111228154A (zh) | 一种婴儿小麦鲜萃原浆乳及其制备方法 | |
| CN117815095A (zh) | 一种具有舒缓修护作用的组合物及其制备方法 | |
| CN117017871A (zh) | 一种发用防脱组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |